N-Terminal domain antiandrogen

EPI-001.svg

N-Terminal domain antiandrogen

N-Terminal domain antiandrogens (NTD antiandrogens) are a class of antiandrogens that specifically target the N-terminal domain (NTD) of the androgen receptor (AR). Unlike conventional antiandrogens that bind to the ligand-binding domain (LBD) of the AR, NTD antiandrogens inhibit the activity of the AR by interacting with its N-terminal domain, which is crucial for the transcriptional activity of the receptor.

Mechanism of Action

The androgen receptor is a type of nuclear receptor that is activated by binding to androgens, such as testosterone and dihydrotestosterone (DHT). The AR consists of several domains, including the N-terminal domain, the DNA-binding domain (DBD), the hinge region, and the ligand-binding domain. The NTD is essential for the receptor's transcriptional activity and interaction with coactivators.

NTD antiandrogens work by binding to the N-terminal domain of the AR, thereby preventing the receptor from interacting with coactivators and other transcriptional machinery. This inhibition reduces the expression of AR target genes, which are involved in the growth and survival of prostate cancer cells.

Clinical Applications

NTD antiandrogens are being investigated for their potential use in the treatment of castration-resistant prostate cancer (CRPC), a form of prostate cancer that no longer responds to conventional androgen deprivation therapy (ADT). By targeting the N-terminal domain, these antiandrogens offer a novel approach to inhibiting AR activity in CRPC, where the AR often remains active despite low levels of circulating androgens.

Examples

One of the most well-known NTD antiandrogens is EPI-001, which has shown promise in preclinical studies for its ability to inhibit AR activity and reduce tumor growth in prostate cancer models. Other NTD antiandrogens are currently under development and investigation.

Research and Development

Research into NTD antiandrogens is ongoing, with several compounds being evaluated in preclinical and clinical studies. These studies aim to determine the efficacy, safety, and potential side effects of NTD antiandrogens in the treatment of prostate cancer and other AR-related conditions.

See Also

• Androgen receptor
• Antiandrogen
• Prostate cancer
• Castration-resistant prostate cancer
• Androgen deprivation therapy

External Links

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian